The Differences of Quantitative Flow Ratio in Coronary Artery Stenosis with or without Atrial Fibrillation

Table 2

Baseline procedural characteristics.

Characteristics	AF patients (n = 112)	Control group (n = 111)
ACS patients	17 (15.18%)	14 (12.16%)
Number of drug-eluting stents
1	96 (85.71%)	84 (75.68%)
2	16 (14.29%)	26 (23.42%)
≥3	0 (0%)	1 (0.90%)
PCI vessel
LAD	61 (54.46%)	74 (66.67%)
LCX	18 (16.07%)	30 (27.03%)
RCA and other vessels	33 (29.46%)	7 (6.31%)
Periprocedural treatment
Antiplatelet agent	112 (100%)	111 (100%)
GPIIbIIIa	20 (17.86%)	25 (22.52%)
Anticoagulants	109 (97.32%)	20 (18.02%)
β-Blocker	95 (84.82%)	97 (87.39%)
Statin	105 (93.75%)	107 (96.40%)
ACEI/ARB/ARNI	59 (52.68%)	48 (43.24%)

Data are expressed as n (%). ACS, acute coronary syndrome; GPIIbIIIIa, glycoprotein IIbIIIa receptor blocker; LAD, left anterior descending artery; LCX, left circumflex artery; LM, left main coronary artery; PCI, percutaneous coronary intervention; RCA, right coronary artery. Antiplatelet agent refers to aspirin and clopidogrel or ticagrelor. Anticoagulants refer to warfarin or low molecular heparin or novel oral anticoagulant. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor.